中文
Earlier issues
Announcement
More
Progress in Chemistry 2014, Vol. 26 Issue (09): 1527-1536 DOI: 10.7536/PC140313 Previous Articles   Next Articles

Special Issue: 酶化学

• Review •

Cyclopeptide Histone Deacetylase Inhibitors

Li Xiaohui*, Huang Meiling, Liu Lina, Wang Yanyun   

  1. School of Life Science and Biotechnology, Dalian University of Technology, Dalian 116024, China
  • Received: Revised: Online: Published:
PDF ( 1422 ) Cited
Export

EndNote

Ris

BibTeX

Histone deacetylase inhibitor is a novel class of histone deacetylase targeted anti-cancer drug, which takes excellent effects on anti-proliferation, pro-apoptosis, pro-differentiation, cell cycle arrest, anti-angiogenesis and so on. Histone deacetylase inhibitor plays an important role in the development of anticancer drug with its unique anti-tumor mechanism. Among the histone deacetylase inhibitors, the cyclopeptide histone deacetylase inhibitor with the most complicated structure has good antagonism on various types of solid tumors and hematologic cancer. In this review, the structural features of the metal binding region, the surface recognition region and the linker region of natural and synthetic cyclic peptide histone deacetylase inhibitors are summarized, and the inhibitory activity and anti-tumor proliferative activity of various inhibitors are described. Modification of different structure domains can make inhibitors with high efficiency and specificity on different tumor cells. We expect to find the structure rule of the high efficient and low toxic targeted peptide inhibitors through structure-activity relationships, providing new sights for investigation of anti-cancer drugs.

Contents
1 Introduction
2 Histone deacetylase inhibitors and classification
3 Cyclopeptide histone deacetylase inhibitors
3.1 Cyclopeptide histone deacetylase inhibitors containing ketone
3.2 Cyclopeptide histone deacetylase inhibitors containing hydroxamic acid
3.3 Cyclopeptide histone deacetylase inhibitors containing sulfur
3.4 Cyclopeptide histone deacetylase inhibitors containing carboxylic acid or amide
3.5 Other histone deacetylase inhibitors
4 Conclusion

Key words: histone deacetylase, histone deacetylase inhibitor, cyclic peptides, anti-tumor

CLC Number: 

[1] Cortez C C, Jones P A. Mutation Research, 2008, 647(1/2): 44.
[2] Cortez C C, Jones P A. European Journal of Medicinal Chemistry, 2005, 40(1): 1.
[3] Weichert W. Cancer Letters, 2009, 280(2): 168.
[4] Ropero S, Esteller M. Molecular Oncology, 2007, 1(1):19.
[5] Somech R, Izraeli S, Simon A J. Cancer Treatment Reviews, 2004, 30(5): 461.
[6] Liu T, Kuljaca S, Tee A, Marshall G M. Cancer Treatment Reviews, 2006, 32(3): 157.
[7] Smith K T, Workman J L. The International Journal of Biochemistry & Cell Biology, 2009, 41(1): 21.
[8] Abujamra A L, dos Santos M P, Roesler R, Schwartsmann G, Brunetto A L. Leukemia Research,2010, 34(6): 687.
[9] Perego P, Zuco V, Gatti L, Zunino F. Biochemical Pharmacology, 2012, 83(8): 987.
[10] Dell'Aversana C, Lepore I, Altucci L. Experimental Cell Research, 2012, 318(11): 1229.
[11] Seidel C, Florean C, Schnekenburger M, Dicato M, Diederich M. Biochimie, 2012, 94(11): 2264.
[12] Harrison I F, Dexter D T. Pharmacology & Therapeutics, 2013, 140(1): 34.
[13] Finnin M S, Donigian J R, Cohen A, RichonV M, Rifkind R A, Marks P A, Breslow R, Pavletich N P. Nature,1999, 401(6749): 188.
[14] Witt O, Deubzer H E, Milde T, Oehme I. Cancer Letters, 2009, 277(1): 8.
[15] Hess-Stumpp H. European Journal of Cell Biology, 2005, 84(2/3): 109.
[16] Henderson C, Brancolini C. Drug Resistance Updates, 2003, 6(5): 247.
[17] Johnstone R W, Licht J D. Cancer Cell, 2003,4(1): 13.
[18] Carew J S, Giles F J, Nawrocki S T. Cancer Letters, 2008, 269(1): 7.
[19] New M, Olzscha H, La Thangue N B. Molecular Oncology, 2012, 6(6): 637.
[20] Fulda S.Experimental Cell Research, 2012, 318(11): 1208.
[21] Seidel C, Schnekenburger M, Dicato M, Diederich M. Genes Nutr., 2012, 7(3): 357.
[22] Yoshida M, Horinouchi S, Beppu T. Bioassays, 1995,17(5): 423.
[23] Closse A, Huguenin R. Helv. Chim. Acta,1974, 57: 553.
[24] Rich D H, Gardner J H. Tetrahedron Letters, 1983, 24(48): 5305.
[25] Tani H, Honma T, Fujii Y, Yoneyama K, Nakajima H. Phytochemistry, 2003, 62(7): 1133.
[26] De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, Janicot M, Arts J, Van heusden J. The Journal of Pharmacology and Experimental Therapeutics, 2003, 304(2):881.
[27] Furumai R, Komatsu Y, Nishino N,Khochbin S, Yoshida M, Horinouchi S.Proc. Natl. Acad. Sci. U. S. A., 2001, 98(1): 87.
[28] Deubzer H E, Ehemann V, Kulozik A E, Westermann F, Savelyeva L, Kopp-Schneider A, Riester D, Schwab M, Witt O. Cancer Letters, 2008, 264(1): 21.
[29] Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, Schwab M, Witt O. Int. J. Cancer, 2008, 122(8): 1891.
[30] Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H, Terui A, Yoshimatsu S, Ikenishi Y, Nakagawa Y. J. Antibiot.,1990, 63(12): 1524.
[31] Kijima M, Yoshida M, Sugita K,Horinouchi S, Beppu T.J. Biol. Chem., 1993, 268(30): 22429.
[32] Taunton J, Collins JL, Schreiber SL.J. Am. Chem. Soc., 1996, 118(43): 10412.
[33] Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Journal of Biological Chemistry, 1993, 268(30): 22429.
[34] Hirota A, Suzuki A, Suzuki H, Tamura S. Agr. Biol. Chem.,1973, 37(3): 643.
[35] Hirota A, Suzuki A, Aizawa K, Tamura S. Agr. Biol. Chem.,1973, 37(4): 955.
[36] Hirota A, Suzuki A, Tamura S. Agr. Biol. Chem.,1973, 37(5): 1185.
[37] Umehara K, Nakahara K, Kiyoto S, Iwami M, Okamoto M, Tanaka H, Kohsaka M, Aoki H, Imanaka H. J. Antiobiot.,1983, 36(5): 478.
[38] Petrella A, D'Acunto C W, Rodriquez M, Festa M, Tosco A, Bruno I, Terracciano S, Taddei M, Paloma L G, Parente L. European Journal of Cancer, 2008, 44(5): 740.
[39] D'Acunto C W, Fontanella B, Rodriquez M, Taddei M, Parente L, Petrella A. Cancer Letters, 2010, 295(1): 85.
[40] Terracciano S, Di Micco S, Bifulco G, Gallinari P, Riccio R, Bruno I. Bioorganic & Medicinal Chemistry, 2010, 18(9): 3252.
[41] Singh S B, Zink D L, Polishook J D, Dombrowski A W, Darkin-Rattray S J, Schmatz D M, Goetz M A. Tetrahedron Letters, 1996, 37(45): 8077.
[42] Kim S H, Ahn S, Han J W, Lee H W, Lee H Y, Lee Y W, Kim M R, Kim K W, Kim W B, Hong S. Biochemical and Biophysical Research Communications, 2004, 315(4): 964.
[43] Kim Y K, Seo D W, Kang D W, Lee H Y, Han J W, Kim S N. Biochemical and Biophysical Research Communications, 2006, 347(4): 1088.
[44] Ahn M Y, Ahn S G, Yoon J H. Oral Oncology, 2011, 47(11): 1032.
[45] Ahn M Y, Kang D O, Na Y J, Yoon S, Choi W S, Kang K W, Chung H Y, Jung J H, Min D S, Kim H S. Cancer Letters, 2012, 325(2): 189.
[46] Hong J J, Ishihara K, Yamaki K, Hiraizumi K, Ohno T, Ahn J W, Zee O, Ohuchi K. Cancer Letters, 2003, 189(2): 197.
[47] Lai J P, Sandhu D S, Moser C D, Cazanave S C, Oseini A M, Shire A M, Shridhar V, Sanderson S O, Roberts L R. Journal of Hepatology, 2009, 50(6): 1112.
[48] Dbicki S, Jagodzinski P P. Biomedicine & Pharmacotherapy,2009, 63(7): 543.
[49] Montero A, Beierle J M, Olsen C A, Ghadiri M R. J. Am. Chem. Soc., 2009, 131(8): 3033.
[50] Jose B, Oniki Y, Kato T, Nishino N, Sumida Y, Yoshida M. Bioorganic & Medicinal Chemistry Letters, 2004, 14(21): 5343.
[51] Nishino N, Yoshikawa D, Watanabe L A, Kato T, Jose B, Komatsu Y, Sumida Y, Yoshida M. Bioorganic& Medicinal Chemistry Letters, 2004, 14(10): 2427.
[52] Islam S, Bhuiyan M P I, Islam N, Nsiama T K, Oishi N, Kato T, Nishino N, Ito A, Yoshida M. Amino Acids, 2012, 42(6): 2103.
[53] Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(1): 87.
[54] Komatsu Y, Tomizaki K, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H. Cancer Research, 2001, 61: 4459.
[55] Nishino N, Jose B, Shinta R, Kato T, Komatsu Y, Yoshida M. Bioorganic & Medicinal Chemistry, 2004, 12: 5777
[56] Islam N M, Kato T, Nishino N, Kim H J, Ito A, Yoshida M. Bioorganic & Medicinal Chemistry Letters, 2010, 20(3): 997.
[57] Li X H, Huang M L, Wang S M, Wang Q. Asian Pac. J. Cancer Prev., 2013, 14(12): 7095.
[58] Jose B, Okamura S, Kato T, Nishino N, Sumida Y, Yoshida M. Bioorganic & Medicinal Chemistry, 2004, 12(6): 1351.
[59] Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. J. Antibio., 1994, 47(3):301.
[60] Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T. J. Antibio., 1994, 47(3):311.
[61] Narita K, Kikuchi T, Watanabe K, Takizawa T, Oguchi T, Kudo K, Matsuhara K, Abe H, Yamori T, Yoshida M, Katoh T. Chem. Eur. J., 2009, 15(42): 11174.
[62] Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S.Cancer Res., 2002, 62(17): 4916.
[63] 陈忠南 (Chen Z N), 徐克前 (Xu K Q). 国际病理科学与临床杂志 (International Journal of Pathology and Clinical Medicine), 2008, 28(4): 297.
[64] Yuhta M, Nobuaki S, Noriaki I. Progress in Drug Research, 2008, (26): 337.
[65] Lai M T, Yang C C, Lin T Y, Tsai F J, Chen W C.Urologic Oncology: Seminars and Original Investigations, 2008, 26(2): 182.
[66] VanderMolen K M, McCulloch W, Pearce C J, Oberlies N H.The Journal of Antibiotics, 2011, 64(8): 525.
[67] Wilson A J, Lalani A S, Wass E, Saskowski J, Khabele D.Gynecologic Oncology, 2012, 127(3): 579.
[68] Masuoka Y, Nagai A, Shin-ya K, Furihata K, Nagai K, Suzuki K, Hayakawa Y, Seto H. Tetrahedron Lett., 2001, 42(1): 41.
[69] Yurek-George A, Habens F, Brimmell M, Packham G, Ganesan A. J. Am. Chem. Soc.,2004, 126(4): 1030.
[70] Taori K, Paul VJ, Luesch H. J. Am. Chem. Soc.,2008, 130(6): 1806.
[71] Ying Y C, Taori K, Kim H, Hong J, Luesch H. J. Am. Chem. Soc.,2008, 130(26): 8455.
[72] Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, Williams RM. J. Am. Chem. Soc., 2008, 130(33): 11219.
[73] Bowers A A, West N, Newkirk T L, Troutman-Youngman A E, Schreiber S L, Wiest O, Bradner J E, Williams R M.Org. Lett., 2009, 11(6): 1301.
[74] Nishino N, Jose B, Okamura S, Ebisusaki S, Kato T, Sumida Y, Yoshida M. Organic Letters, 2003, 5(26): 5079.
[75] Shivashimpi G M, Amagai S, Kato T, Nishino N, Maeda S, Nishino T G, Yoshida M. Bioorganic & Medicinal Chemistry, 2007, 15(24): 7830.
[76] Huang D W, Li X H, Sun L, Xiu Z L, Nishino N.Journal of Peptide Science, 2012,18(4): 242.
[77] Li X H, Wei Y D, Wang S M,Wang M N, Huang D W, Xiu Z L.Chem. Res. Chin. Univ., 2012, 28(6): 1011.
[78] Nishino N, Shivashimpi G M, Soni P B, Bhuiyan M P I, Kato T, Maeda S, Nishino T G, Yoshida M. Bioorganic & Medicinal Chemistry, 2008, 16(1): 437.
[79] Hoque A, Arai T, Nishino N, Kim H J, Ito A, Yoshida M. Bioorganic & Medicinal Chemistry Letters, 2012, 22(21): 6770.
[80] Arai T, Hoque A, Nishino N, Kim H J, Ito A, Yoshida M. Amino Acids, 2013,45(4):835.
[81] Narita K, Fukui Y, Sano Y, Yamori T, Ito A, Yoshida M, Katoh T. European Journal of Medicinal Chemistry, 2013, 60: 295.
[82] Nakao Y, Yoshida S, Matsunaga S, Shindoh N, Terada Y, Nagai K, Yamashita JK, Ganesan A, van Soest R W M, Fusetani N. Angew. Chem. Int. Ed., 2006, 45(45): 7553.
[83] Maulucci N, Chini M G, Di Micco S, Izzo I, Cafaro E, Russo A, Gallinari P, Paolini C, Nardi M C, Casapullo A, Riccio R, Bifulco G, De Riccardis F. J. Am. Chem. Soc., 2007, 129(10): 3007.
[84] Izzo I, Maulucci N, Bifulco G, de Riccardis F. Angew. Chem. Int. Ed., 2006, 45(45): 7557.
[85] Uesato S, Kitagawa M, Nagaoka Y, Maeda T, Kuwajima H, Yamori T. Bioorg. Med. Chem. Lett., 2002, 12(10): 1347.
[86] Lu Q, Yang Y T, Chen C S, Davis M, Byrd J C, Etherton M R, Umar A, Chen C S. J. Med. Chem., 2004, 47(2): 467.
[87] Bhuiyan M P I, Kato T, Okauchi T, Nishino N, Maeda S, Nishino T G, Yoshida M. Bioorganic & Medicinal Chemistry, 2006, 14(10): 3438.
[88] Singh E K, Ravula S,Pan C M,Pan P O, Vasko R C, Lapera S A, Weerasinghe S V W, Pflum M K H, McAlpine S R. Bioorg.Med.Chem.Lett., 2008,18(8): 2549.
[89] Singh E K, Nazarova L A, Lapera S A, Alexander L D, McAlpine S R. Tetrahedron Letters, 2010, 51(33): 4357.
[1] Xinyu Wang, Fuping Zhao, Ru Zhang, Ziru Sun, Shengnan Liu, Qingzhi Gao. Development of Hypoxia Inducible Factor-1 Small Molecule Inhibitors as Antitumor Agents [J]. Progress in Chemistry, 2021, 33(12): 2259-2269.
[2] Li Sidi, Hou Xin, Qi Hongzhao, Zhao Jin, Yuan Xubo. Exosomes:Provide Naturally Occurring Endogenous Nanocarriers for Effective Drug Delivery Strategies [J]. Progress in Chemistry, 2016, 28(2/3): 353-362.
[3] Wang Jiamin, Shi Lei, Liu Haiyang. The Interaction of Corrole and Its Metal Complex with DNA and Their Anti-Tumor Activity [J]. Progress in Chemistry, 2015, 27(6): 755-762.
[4] Liang Yanyu, Tang Shan, Zheng Jishen. Cell-Permeable Cyclic Peptides [J]. Progress in Chemistry, 2014, 26(11): 1793-1800.
[5] Cui Jianguo, Liu Liang, Gan Chunfang, Xiao Qi, Huang Yanmin. Synthesis and Biological Activity of Steroids Bearing Aromatic Rings and Heterocycles [J]. Progress in Chemistry, 2014, 26(0203): 320-333.
[6] Huang Yanmin, Cui Jianguo, Gan Chunfang, Yao Qiucui, Jia Linyi. Steroidal Amides with Biological Activities [J]. Progress in Chemistry, 2012, 24(01): 61-69.
[7] Zhang Xiaonian, Liu Yanan, Yang Xiaoxin, Liu Jie. Apoptotic Signal Pathways of Tumor Cells Induced by Ruthenium Complexes and Its Mechanisms [J]. Progress in Chemistry, 2011, 23(5): 983-990.
[8] Li Xiaohui1**|Li Jianxun1|Li Shirong1,Xiu Zhilong1,Nishino Norikazu2. Cyclic Peptide Histone Deacetylases Inhibitors [J]. Progress in Chemistry, 2007, 19(05): 762-768.
[9] Wu Zhenyu,Zhang Yunhong,Wang Hui,Ma Fengqi. Research on Design and Synthesis of Cyclic Peptides [J]. Progress in Chemistry, 2002, 14(02): 113-.